Rocket Q3 2021 Earnings Report
Key Takeaways
Rocket Pharmaceuticals reported a net loss of $50.1 million for the third quarter of 2021. The company's cash, cash equivalents, and investments totaled $421.5 million as of September 30, 2021, which is expected to fund operations into the second half of 2023.
Treatment initiated in pediatric patient cohort in Danon Disease trial of RP-A501
Treatment completed in nine of nine patients in LAD-1 Phase 1/2 trial; favorable safety profile and initial clinical benefit reported in all seven patients with at least 3 months of follow up
Clinical updates anticipated in Danon Disease at AHA 2021 Scientific Sessions and in FA, LAD-I and PKD at 63rd ASH Annual Meeting
Ending Balance Sheet with $421.5 Million in Cash; Cash Runway Expected into 2H’23
Rocket
Rocket
Forward Guidance
Rocket expects its balance in cash, cash equivalents and investments of $421.5 million as of September 30, 2021 to fund its operations into the second half of 2023.